Philip Reilly
Director/Board Member at Gemini Therapeutics Sub, Inc.
Profile
Phil focuses on creating and building companies that develop breakthrough therapies for orphan genetic diseases.
He is passionate about working with patient groups, and helping to unite those suffering from rare diseases in order to foster a support network and potentially improve patient outcomes.
Phil has authored or co-authored more than 100 articles in scholarly journals and has published seven books including most recently Orphan: The Quest to Save Children with Rare Genetic Disorders.
Phil currently serves on the Advisory Board to the Boston University School of Public Health, and has served as a trustee emeritus of Cornell University, an Overseer of Weill Cornell Medical College.
Philip Reilly active positions
| Companies | Position | Start |
|---|---|---|
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Private Equity Investor | 2007-12-31 |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY. | Director/Board Member | 2010-06-02 |
Gemini Therapeutics Sub, Inc.
 Gemini Therapeutics Sub, Inc. BiotechnologyHealth Technology Gemini Therapeutics Sub, Inc. engages in the development of treatments for age-related macular degeneration (AMD) and linked ocular disorders. Its multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. The company was founded by James McLaughlin, Johanna Seddon, Paul Barlow and Andrew Herbert in 2015 and is headquartered in Cambridge, MA. | Director/Board Member | - |
Stellular Bio, Inc.
 Stellular Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Stellular Bio, Inc. develops technology to produce independent human platelets from human induced pluripotent stem cells. The company was founded by Jonathan Thon, Joseph Italiano and Sven Karlsson in 2014 and is headquartered in Watertown, MA. | Director/Board Member | - |
Former positions of Philip Reilly
| Companies | Position | End |
|---|---|---|
Edimer Pharmaceuticals, Inc.
 Edimer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Edimer Pharmaceuticals, Inc. provides biopharmaceutical products for improving the health and quality of life of families living with XLHED. It has developed EDI200 as a treatment for X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), which is a rare orphan disease that causes symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations. The company was founded by Pascal Schneider and Olivier Gaide in 2009 and is headquartered in Cambridge, MA. | Director/Board Member | 2016-12-30 |
| INTERLEUKIN GENETICS, INC | Chairman | - |
| VOYAGER THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Lotus Tissue Repair, Inc.
 Lotus Tissue Repair, Inc. Pharmaceuticals: MajorHealth Technology Lotus Tissue Repair, Inc. develops dermatologic treatment technologies. Its solutions include a protein replacement therapy for the treatment of dystrophic epidermolysis bullosa, a group of genetic skin disease. The company was founded by Mei Chen, Mark P. de Souza, Philip R. Reilly, David Woodley and James W. Fordyce in 2011 and is headquartered in Lexington, MA. | Founder | - |
| BLUEBIRD BIO, INC. | Chief Tech/Sci/R&D Officer | - |
Training of Philip Reilly
| Cornell University | Undergraduate Degree |
| The Trustees of Columbia University in The City of New York | Graduate Degree |
| Yale University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| BLUEBIRD BIO, INC. | Health Technology |
| VOYAGER THERAPEUTICS, INC. | Health Technology |
| Private companies | 6 |
|---|---|
Interleukin Genetics, Inc.
 Interleukin Genetics, Inc. Pharmaceuticals: MajorHealth Technology Interleukin Genetics, Inc. engages in the marketing and development of proprietary genetic tests for chronic inflammatory diseases and health-related conditions focuses on metabolism and inflammation. The company was founded in 1986 and is headquartered in Waltham, MA. | Health Technology |
Third Rock Ventures LLC
Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Finance |
Edimer Pharmaceuticals, Inc.
Edimer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Edimer Pharmaceuticals, Inc. provides biopharmaceutical products for improving the health and quality of life of families living with XLHED. It has developed EDI200 as a treatment for X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), which is a rare orphan disease that causes symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations. The company was founded by Pascal Schneider and Olivier Gaide in 2009 and is headquartered in Cambridge, MA. | Health Technology |
Lotus Tissue Repair, Inc.
Lotus Tissue Repair, Inc. Pharmaceuticals: MajorHealth Technology Lotus Tissue Repair, Inc. develops dermatologic treatment technologies. Its solutions include a protein replacement therapy for the treatment of dystrophic epidermolysis bullosa, a group of genetic skin disease. The company was founded by Mei Chen, Mark P. de Souza, Philip R. Reilly, David Woodley and James W. Fordyce in 2011 and is headquartered in Lexington, MA. | Health Technology |
Gemini Therapeutics Sub, Inc.
Gemini Therapeutics Sub, Inc. BiotechnologyHealth Technology Gemini Therapeutics Sub, Inc. engages in the development of treatments for age-related macular degeneration (AMD) and linked ocular disorders. Its multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. The company was founded by James McLaughlin, Johanna Seddon, Paul Barlow and Andrew Herbert in 2015 and is headquartered in Cambridge, MA. | Health Technology |
Stellular Bio, Inc.
Stellular Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Stellular Bio, Inc. develops technology to produce independent human platelets from human induced pluripotent stem cells. The company was founded by Jonathan Thon, Joseph Italiano and Sven Karlsson in 2014 and is headquartered in Watertown, MA. | Commercial Services |
- Stock Market
- Insiders
- Philip Reilly